<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296023</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000463724</org_study_id>
    <secondary_id>UCSF-98251</secondary_id>
    <secondary_id>UCSF-9805</secondary_id>
    <secondary_id>UCSF-H9996-15837-06</secondary_id>
    <nct_id>NCT00296023</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer</brief_title>
  <official_title>Low-Dose Allogeneic Peripheral Blood Stem Cell Transplantation for High-Risk Low Grade Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor
      bone marrow or peripheral blood stem cell transplant helps stop the growth of cancer cells.
      It also stops the patient's immune system from rejecting the donor's stem cells. The donated
      stem cells may replace the patient's immune system and help destroy any remaining cancer
      cells (graft-versus-tumor effect). Giving an infusion of the donor's T cells (donor
      lymphocyte infusion) after the transplant may help increase this effect. Sometimes the
      transplanted cells from a donor can also make an immune response against the body's normal
      cells. Giving antithymocyte globulin before transplant and methotrexate and tacrolimus after
      the transplant may stop this from happening.

      PURPOSE: This phase I trial is studying the side effects of donor stem cell transplant in
      treating older or frail patients with hematologic cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the safety of non-myeloablative allogeneic peripheral blood stem cell
           transplantation, in terms of regimen-related organ toxicity and toxicity from acute
           graft-vs-host disease (GVHD), in older or medically frail patients with high-risk
           indolent hematologic malignancies.

        -  Determine overall survival, disease-free survival, and relapse risk at 1, 2, and 3 years
           post-transplantation in these patients.

      Secondary

        -  Determine the engraftment of donor hematopoiesis at 6 weeks, 3 and 6 months, and 1 year
           post-transplantation in these patients.

        -  Determine the incidence and severity of chronic GVHD in older and medically infirm
           patients treated with this regimen.

        -  Determine the safety and efficacy of collecting peripheral blood stem cells from older
           donors (age &gt; 60 years).

        -  Determine the need and efficacy of donor lymphocyte infusions in patients with residual
           disease after transplant.

      OUTLINE:

        -  Non-myeloablative preparative regimen:Patients receive fludarabine IV over 30 minutes on
           days -7 to -3, busulfan IV over 2 hours every 8 hours on days -4 and -3, and
           anti-thymocyte globulin IV over 8 hours on days -4 to -1.

        -  Transplantation: Patients undergo allogeneic peripheral blood stem cell transplantation
           on day 0. Patients receive filgrastim (G-CSF) subcutaneously beginning on day 6 and
           continuing until blood counts recover.

        -  Graft-vs-host disease (GVHD) prophylaxis: Patients receive tacrolimus orally every 12
           hours or IV continuously beginning on day -2 and continuing until day 90, followed by a
           taper until day 180. Patients also receive methotrexate IV over 15-30 minutes on days 1,
           3, 6, and 11.

        -  Donor lymphocyte infusions (DLIs): Patients with residual disease ≥ 6 months
           post-transplantation who are off immunosuppression for ≥ 30 days with no evidence of
           GVHD may receive DLIs. DLIs are administered ≥ 12 weeks apart in the presence of
           persistent disease, absence of severe (grade 3-4) GVHD, and absence of persistent GVHD
           after the first DLI.

      After completion of study therapy, patients are followed periodically for 5 years.

      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 1999</start_date>
  <completion_date type="Actual">June 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity and survival</measure>
    <time_frame>up to 36 months post transplant</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <arm_group>
    <arm_group_label>stem cell transplant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>nonmyeloablative allogeneic hematopoietic stem cell transplantation</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>stem cell transplant</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of a high-risk indolent hematologic malignancy meeting the following
             criteria:

               -  Chronic lymphocytic leukemia (CLL) meeting 1 of the following criteria:

                    -  In second or subsequent remission

                    -  Failed to achieve a complete remission (CR) after chemotherapy

               -  Non-Hodgkin's lymphoma (NHL) meeting 1 of the following criteria:

                    -  Low-grade NHL meeting 1 of the following criteria:

                         -  Standard-risk disease in second or subsequent remission

                         -  Standard-risk disease and failed to achieve a CR after chemotherapy

                         -  In first or subsequent remission with adverse International Prognostic
                            Index (IPI) prognostic features, as defined by the presence of ≥ 3 of
                            the following:

                              -  Age &gt; 60 years

                              -  Tumor stage III or IV

                              -  Extranodal disease at &gt; 1 site

                              -  ECOG performance status ≥ 2

                              -  Serum lactic dehydrogenase (LDH) &gt; upper limit of normal (ULN)

                    -  Intermediate- or high-grade NHL meeting 1 of the following criteria:

                         -  In second or subsequent remission

                         -  Failed to achieve a CR after initial chemotherapy

               -  Waldenstrom's macroglobulinemia meeting 1 of the following criteria:

                    -  In second or subsequent remission

                    -  Failed to achieve a CR after initial chemotherapy

               -  Multiple myeloma meeting 1 of the following criteria:

                    -  In first or subsequent remission

                    -  Failed to achieve a CR after initial chemotherapy

               -  Myeloproliferative disorders, including any of the following:

                    -  Chronic myelogenous leukemia in first or subsequent chronic phase

                    -  Myelofibrosis

                    -  Essential thrombocytopenia that is poorly responsive to standard therapy

                    -  Polycythemia vera that is poorly responsive to standard therapy or is in
                       spent phase

               -  Prolymphocytic leukemia meeting 1 of the following criteria:

                    -  In first or subsequent remission

                    -  Failed to achieve a CR after initial chemotherapy

               -  Mantle cell lymphoma meeting 1 of the following criteria:

                    -  In first or subsequent remission

                    -  Failed to achieve a CR after initial chemotherapy

               -  Hodgkin's lymphoma meeting the following criteria:

                    -  In second or subsequent remission

                         -  Prior remission duration &gt; 6 months

                    -  No radiation therapy as the only prior primary therapy

               -  Myelodysplastic syndromes (MDS) meeting 1 of the following criteria:

                    -  Refractory anemia with excess blasts (RAEB)

                    -  RAEB in transformation

                    -  Chronic myelomonocytic leukemia

                    -  Any MDS with transfusion dependence

                    -  Any MDS with ≥ 2 significant infections

               -  Acute myeloid leukemia in morphologic remission

          -  In CR or partial remission or stabilization of disease after standard chemotherapy

               -  No progressive or refractory disease

          -  Not eligible for standard allogeneic bone marrow transplantation

          -  Meets 1 of the following criteria:

               -  Age 60 to 75 years old AND no co-morbid illness

               -  Younger patients with any of the following comorbidities:

                    -  Decreased cardiac ejection fraction

                    -  Pulmonary dysfunction

                    -  Elevated liver function tests

                    -  Hepatitis C infection

                    -  Poor performance status

          -  Sibling or related donor available

               -  Matched ≥ 5/6 HLA loci (A, B, and DR) NOTE: A new classification scheme for adult
                  non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of &quot;indolent&quot; or
                  &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,
                  &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former
                  terminology.

        PATIENT CHARACTERISTICS:

          -  See Disease Characteristics

          -  ECOG performance status 0-2

          -  Creatinine &lt; 2.0 mg/dL

          -  Creatinine clearance &gt; 40 mL/min

          -  Ejection fraction &gt; 30% by echocardiogram or MUGA

          -  Bilirubin &lt; 3.0 mg/dL (if total bilirubin is elevated and Gilbert's disease is
             suspected, direct bilirubin must be normal)

          -  Alkaline phosphatase &lt; 4 times ULN

          -  AST &lt; 4 times ULN

          -  HIV negative

          -  Hepatitis B and/or C virus allowed if a liver biopsy (performed within the past 3
             months) shows ≤ grade 2 inflammation

          -  No active infection

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas G. Martin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Willis Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charles A. Linker, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alta Bates Comprehensive Cancer Center</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2006</study_first_posted>
  <last_update_submitted>October 2, 2012</last_update_submitted>
  <last_update_submitted_qc>October 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 4, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>polycythemia vera</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>refractory anemia with excess blasts in transformation</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>Waldenström macroglobulinemia</keyword>
  <keyword>essential thrombocythemia</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

